IDEAYA Biosciences, Inc. (IDYA)
| Market Cap | 2.47B +42.9% |
| Revenue (ttm) | 225.27M +3,118.1% |
| Net Income | -140.06M |
| EPS | -1.58 |
| Shares Out | 87.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 726,865 |
| Open | 28.26 |
| Previous Close | 28.13 |
| Day's Range | 27.66 - 28.44 |
| 52-Week Range | 16.84 - 39.28 |
| Beta | -0.04 |
| Analysts | Strong Buy |
| Price Target | 53.14 (+88.98%) |
| Earnings Date | May 5, 2026 |
About IDYA
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhib... [Read more]
Financial Performance
In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price target is $53.14, which is an increase of 88.98% from the latest price.
News
Ideaya Biosciences price target lowered to $50 from $52 at Mizuho
Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $50 from $52 and keeps an Outperform rating on the shares.
Ideaya Biosciences reports Q1 EPS ($1.11), consensus (98c)
Reports Q1 revenue $6.56M, consensus $5.04M. “This was a transformational quarter for IDEAYA, with positive topline results from the OptimUM-02 registrational trial in first line HLA*A2-negative metas...
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO IDEAYA to initiate RTOR su...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeut...
Ideaya Biosciences announces darovasertib combination NDA to be reviewed by FDA
Ideaya Biosciences (IDYA) announced that the FDA has agreed to review its new drug application for darovasertib in combination with crizotinib for patients with first line HLA A2-negative metastatic u...
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint and will be presented in a late-breaking oral presentation at ASCO 2026 IDEAYA to initiate the RTOR sub...
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-b...
Ideaya Biosciences price target raised to $58 from $52 at Wedbush
Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $58 from $52 and keeps an Outperform rating on the shares. The firm notes the company reported topline data…
Ideaya Biosciences price target raised to $54 from $50 at Guggenheim
Guggenheim analyst Paul Jeng raised the firm’s price target on Ideaya Biosciences (IDYA) to $54 from $50 and keeps a Buy rating on the shares following positive topline results from…
Ideaya Biosciences price target raised to $53 from $49 at RBC Capital
RBC Capital raised the firm’s price target on Ideaya Biosciences (IDYA) to $53 from $49 and keeps an Outperform rating on the shares. The firm is positive on the meaningfulness…
Ideaya Biosciences price target raised to $65 from $60 at Truist
Truist raised the firm’s price target on Ideaya Biosciences (IDYA) to $65 from $60 and keeps a Buy rating on the shares following topline results from Phase 2/3 registrational trial,…
Ideaya Biosciences rises 22.8%
Ideaya Biosciences (IDYA) is up 22.8%, or $6.96 to $37.46.
IDEAYA Biosciences Transcript: Study result
Darovasertib plus crizotinib significantly improved progression-free survival and response rates in HLA-A2 negative metastatic uveal melanoma, with a favorable safety profile and early signs of overall survival benefit. The combination is poised to become a new standard, with ongoing studies in broader patient populations and earlier disease settings.
Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results
The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its combination therapy for a rare eye cancer.
Ideaya Biosciences, Servier announce topline results from OptimUM-02 trial
Ideaya Biosciences (IDYA) and Servier announced topline results from their Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-lin...
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30, ...
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pr...
Unusually active option classes on open April 8th
Unusual total active option classes on open include: iShares Nasdaq Biotechnology Index Fund (IBB), Vanguard MSCI EAFE (VEA), IDEAYA Biosciences (IDYA), Ally Financial (ALLY), Alaska Air (ALK), Global...
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,0...
Ideaya Biosciences announces first-patient-in for IDE849, IDE161 study
Ideaya Biosciences (IDYA) announced first-patient-in for a Phase 1 clinical trial combination study to evaluate IDE849, a delta-like ligand 3-targeting Topo-I-payload antibody drug conjugate program, ...
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the efficacy and durability of TOP1 ADCs ...
Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release
Ideaya Biosciences (IDYA) provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2-negative metastatic uveal melano...
Ideaya Biosciences falls -6.0%
Ideaya Biosciences (IDYA) is down -6.0%, or -$1.96 to $30.79.
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
SOUTH SAN FRANCISCO, Calif., March 22, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
SOUTH SAN FRANCISCO, Calif., March 18, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for thr...